A cross-sectional study on the expression of fibrinolytic system components and metalloproteinase-9 in women with early-stage and metastases breast cancer in Tucumán, Argentina
Open Access
- 7 April 2025
- journal article
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eAO1237
Abstract
Highlights ■ No clinically significant differences were observed in platelet counts or global coagulation test results. ■ t-PA values decreased in patients with metastases. ■ PAI-1, DD, and MMP-9 levels increased in patients with metastases. ■ High levels of PAI-1 and MMP-9 in the early stages could indicate an aggressive course in patients. ABSTRACT Objective: The hemostatic and matrix metalloproteinase (MMP) systems are known to be altered in patients with breast cancer. This cross-sectional study aimed to explore the fibrinolysisKeywords
This publication has 32 references indexed in Scilit:
- ALDH1A3 promotes invasion and metastasis in triple‐negative breast cancer by regulating the plasminogen activation pathwayMolecular Oncology, 2023
- Clinical significance of plasma MMP‐2 and MMP‐9 levels as biomarkers for tumor expression in breast cancer patients in EgyptMolecular Biology Reports, 2019
- Biochemical and Biological Attributes of Matrix Metalloproteinases2017
- Coagulation tests show significant differences in patients with breast cancerTumor Biology, 2014
- Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancerThe Breast, 2013
- Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patientsEuropean Journal of Cancer, 2013
- Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progressionClinical Biochemistry, 2011
- Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patientsMedical Oncology, 2011
- Tissue-Type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significanceBreast Cancer Research and Treatment, 2005
- Complex of urokinase‐type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node–negative breast carcinomaCancer, 2004